- Home
- RLYB vs PRPO Comparison
RLYB vs PRPO Comparison
Compare RLYB & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- PRPO
- Stock Information
- Founded
- RLYB 2018
- PRPO N/A
- Country
- RLYB United States
- PRPO United States
- Employees
- RLYB N/A
- PRPO N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- RLYB Health Care
- PRPO Industrials
- Exchange
- RLYB Nasdaq
- PRPO Nasdaq
- Market Cap
- RLYB 14.4M
- PRPO 17.1M
- IPO Year
- RLYB 2021
- PRPO N/A
- Fundamental
- Price
- RLYB $0.50
- PRPO $14.70
- Analyst Decision
- RLYB Hold
- PRPO
- Analyst Count
- RLYB 3
- PRPO 0
- Target Price
- RLYB $15.00
- PRPO N/A
- AVG Volume (30 Days)
- RLYB 8.4M
- PRPO 19.1K
- Earning Date
- RLYB 08-07-2025
- PRPO 08-12-2025
- Dividend Yield
- RLYB N/A
- PRPO N/A
- EPS Growth
- RLYB N/A
- PRPO N/A
- EPS
- RLYB N/A
- PRPO N/A
- Revenue
- RLYB $848,000.00
- PRPO $20,029,000.00
- Revenue This Year
- RLYB N/A
- PRPO N/A
- Revenue Next Year
- RLYB N/A
- PRPO N/A
- P/E Ratio
- RLYB N/A
- PRPO N/A
- Revenue Growth
- RLYB N/A
- PRPO 26.67
- 52 Week Low
- RLYB $0.22
- PRPO $3.90
- 52 Week High
- RLYB $1.54
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- RLYB 61.32
- PRPO 61.14
- Support Level
- RLYB $0.42
- PRPO $13.02
- Resistance Level
- RLYB $0.54
- PRPO $14.74
- Average True Range (ATR)
- RLYB 0.07
- PRPO 1.15
- MACD
- RLYB 0.01
- PRPO -0.16
- Stochastic Oscillator
- RLYB 56.61
- PRPO 43.41
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.